已收盘 02-27 16:00:00 美东时间
0.000
NaN.00%
Pasithea Therapeutics appoints Dr. James Lee to its SAB to guide development of PAS-004 for ETS2-driven diseases, including inflammatory bowel disease (IBD). Dr. Lee's research identified ETS2 as a key regulator of IBD inflammation and highlighted MEK inhibitors' effectiveness in suppressing it.
06-11 11:02